Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RXI-109 for Subretinal Fibrosis in NVAMD
NCT02599064Phase 2Unknown
- Sponsor
- Phio Pharmaceuticals
- Start
- Nov 2015
- Primary completion
- Apr 2018
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CTGF siRNA in neovascular age-related macular degeneration (NVAMD), sponsored by Phio Pharmaceuticals. Primary endpoints: Incidence, severity and relationship of Adverse Events at 7 months and Pharmacokinetic profile of RXI-109 in blood at 4 months. Status: unknown.
02
Drugs
CTGF siRNA
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02599064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02599064.